NUTEX HEALTH REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
NUTEX HEALTH REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
- TOTAL REVENUE OF $67.5 MILLION FOR FIRST QUARTER 2024 VS $56.3 MILLION IN 2023, AN INCREASE OF 20%
- HOSPITAL DIVISION VISITS OF 40,068 FOR THE FIRST QUARTER 2024 VS VISITS OF 33,085 IN 2023, AN INCREASE OF 21.1%
- HOSPITAL DIVISION OPERATING INCOME OF $10.5 MILLION FOR FIRST QUARTER 2024 VS $4.8 MILLION IN 2023, AN INCREASE OF 119%
- NET CASH FROM OPERATING ACTIVITIES OF $3.1 MILLION FOR FIRST QUARTER 2024
- CONTINUED FOCUS ON INCREASED CASH FLOW THROUGH REDUCTION IN OPERATING EXPENSES AND PORTFOLIO OPTIMIZATION
- 2024年第一季度的总收入为6,750万美元，而2023年为5,630万美元，增长了20％
- 2024年第一季度的医院分部就诊量为40,068人次，而2023年为33,085人次，增长了21.1％
- 2024年第一季度医院部门的营业收入为1,050万美元，而2023年为480万美元，增长了119％
- 2024年第一季度来自经营活动的净现金为310万美元
- 继续专注于通过减少运营支出和优化投资组合来增加现金流
HOUSTON, May 8, 2024 — Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in nine states and primary care-centric, risk-bearing physician networks, today announced first quarter 2024 financial results for the three months ended March 31, 2024.
休斯顿，2024年5月8日——Nutex Health Inc.（“NUTEX Health” 或 “公司”）（纳斯达克股票代码：NUTX）是一个由医生主导、技术支持的综合医疗保健提供系统，由九个州的21家最先进的微型医院和以初级保健为中心、承担风险的医生网络组成，今天公布了截至2024年3月31日的三个月的2024年第一季度财务业绩。
Financial Highlights for the Three Months Ended March 31, 2024:
截至2024年3月31日的三个月的财务摘要：
- Total revenue of $67.5 million as compared to total revenue of $56.3 million for the three months ended March 31, 2023, an increase of approximately 20%. Of this revenue growth, mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 6.7% in 2024 compared to 2023.
- Total visits from the Hospital Division were 40,068 for the first quarter 2024 as compared to 33,085 for the first quarter 2023, an increase of 6,983 or 21.1%. Of this visit growth, mature hospitals increased by 5.3% in 2024 compared to 2023.
- Net loss attributable to Nutex Health Inc. of $0.4 million as compared to net loss attributable to Nutex Health Inc. of $5.1 million for the three months ended March 31, 2023.
- EBITDA of $7.1 million as compared to EBITDA of $0.3 million for the three months ended March 31, 2023.
- Adjusted EBITDA of $4.6 million as compared to Adjusted EBITDA of $2.4 million for the three months ended March 31, 2023, an increase of 92%.
- Net cash from operating activities of $3.1 million.
- As of March 31, 2024, the Company had total assets of $404.3 million, including cash and cash equivalents of $30.0 million and long-term debt of $26.3 million.
- 总收入为6,750万美元，而截至2023年3月31日的三个月的总收入为5,630万美元，增长了约20％。在这一收入增长中，成熟医院，即2021年12月31日之前开业的医院，在2024年与2023年相比增长了6.7％。
- 2024年第一季度，医院部的总就诊人数为40,068人，而2023年第一季度为33,085人，增长了6,983人，增长了21.1％。在这一就诊量增长中，2024年成熟医院与2023年相比增长了5.3％。
- 归属于Nutex Health Inc.的净亏损为40万美元，而截至2023年3月31日的三个月，归属于Nutex Health Inc.的净亏损为510万美元。
- 息税折旧摊销前利润为710万美元，而截至2023年3月31日的三个月，息税折旧摊销前利润为30万美元。
- 调整后的息税折旧摊销前利润为460万美元，而截至2023年3月31日的三个月，调整后的息税折旧摊销前利润为240万美元，增长了92％。
- 来自经营活动的净现金为310万美元。
- 截至2024年3月31日，该公司的总资产为4.043亿美元，其中包括3000万美元的现金和现金等价物以及2630万美元的长期债务。
Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release.
注意：息税折旧摊销前利润和调整后息税折旧摊销前利润是非公认会计准则财务指标。本财报中包含了非公认会计准则与公认会计准则指标的对账。
"We are pleased to report 20% revenue growth, Adjusted EBITDA of $4.6 million and a 119% increase in hospital division operating income to $10.5 million in 2024, with overall Nutex operating income of $1.5 million as opposed to an operating loss of $4.5 million in the same period last year," stated Jon Bates, Chief Financial Officer of Nutex Health.
Nutex Health首席财务官乔恩·贝茨表示：“我们很高兴地宣布，2024年，收入增长了20％，调整后的息税折旧摊销前利润为460万美元，医院部门的营业收入增长了119％，达到1,050万美元，而去年同期的营业亏损为450万美元。”
"We had a solid First Quarter with strong year over year growth. Volume continues to increase at both our mature hospitals as well as the four hospitals that we opened in 2023. Our average payment by insurers of patient claims increased, a trend we are optimistic will persist as we continue to work the NSA claims through the Independent Dispute Resolution process," stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health.
“我们的第一季度表现稳健，同比增长强劲。我们的成熟医院以及我们在2023年开设的四家医院的数量持续增加。Nutex Health董事长兼首席执行官汤姆·沃医学博士、工商管理硕士、工商管理硕士、工商管理硕士汤姆·沃表示，随着我们继续通过独立争议解决程序处理国家安全局的索赔，我们乐观地认为，这一趋势将持续下去。
"Nutex Health has generated net cash from operations and has had positive Adjusted EBITDA for multiple consecutive quarters while growing organically with the opening of five new micro hospitals and growing our population health division in the past 18 months. We believe our balance sheet is strong, with $30.0 million in cash and only $26.3 million in long-term debt," stated Warren Hosseinion, M.D., President of Nutex Health.
“Nutex Health通过运营产生了净现金，调整后的息税折旧摊销前利润连续多个季度为正，同时在过去18个月中，随着五家新的微型医院的开业和人口健康部门的增长，Nutex Health实现了有机增长。我们认为我们的资产负债表强劲，有3000万美元的现金，只有2630万美元的长期债务。” Nutex Health总裁沃伦·霍塞尼恩医学博士说。
For more details on the Company's First Quarter 2024 financial results, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov.
有关公司2024年第一季度财务业绩的更多详情，请参阅我们向美国证券交易委员会提交的10-Q表季度报告，可在以下网址查阅 www.sec.gov。
| NUTEX HEALTH INC. | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (Unaudited) | ||||||
| March 31, 2024 | December 31, 2023 | |||||
| Assets | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 30,006,419 | $ | 22,002,056 | ||
| Accounts receivable | 61,533,245 | 58,624,301 | ||||
| Accounts receivable – related parties | 4,213,847 | 4,152,068 | ||||
| Inventories | 2,975,486 | 3,390,584 | ||||
| Prepaid expenses and other current assets | 1,629,346 | 2,679,394 | ||||
| Total current assets | 100,358,343 | 90,848,403 | ||||
| Property and equipment, net | 80,570,705 | 81,387,649 | ||||
| Operating right-of-use assets | 11,580,253 | 11,853,082 | ||||
| Finance right-of-use assets | 173,920,659 | 176,146,329 | ||||
| Intangible assets, net | 20,102,371 | 20,512,636 | ||||
| Goodwill, net | 17,066,263 | 17,066,263 | ||||
| Other assets | 685,260 | 431,135 | ||||
| Total assets | $ | 404,283,854 | $ | 398,245,497 | ||
| Liabilities and Equity | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 17,217,905 | $ | 18,899,196 | ||
| Accounts payable – related parties | 6,856,962 | 6,382,197 | ||||
| Lines of credit | 2,777,128 | 3,371,676 | ||||
| Current portion of long-term debt | 9,388,455 | 10,808,721 | ||||
| Operating lease liabilities, current portion | 1,586,904 | 1,579,987 | ||||
| Finance lease liabilities, current portion | 4,366,696 | 4,315,979 | ||||
| Accrued expenses and other current liabilities | 17,694,134 | 12,955,296 | ||||
| Total current liabilities | 59,888,184 | 58,313,052 | ||||
| Long-term debt, net | 26,308,017 | 26,314,733 | ||||
| Warrant liability | 5,060,810 | – | ||||
| Operating lease liabilities, net | 15,097,284 | 15,479,639 | ||||
| Finance lease liabilities, net | 212,867,062 | 213,886,213 | ||||
| Deferred tax liabilities | 5,050,347 | 5,145,754 | ||||
| Total liabilities | 324,271,704 | 319,139,391 | ||||
| Commitments and contingencies | ||||||
| Equity: | ||||||
| Common stock, $0.001 par value; 950,000,000 shares authorized; 49,719,375 and | 49,719 | 45,112 | ||||
| Additional paid-in capital | 472,405,834 | 470,480,617 | ||||
| Accumulated deficit | (409,436,614) | (409,072,539) | ||||
| Nutex Health Inc. equity | 63,018,939 | 61,453,190 | ||||
| Noncontrolling interests | 16,993,211 | 17,652,916 | ||||
| Total equity | 80,012,150 | 79,106,106 | ||||
| Total liabilities and equity | $ | 404,283,854 | $ | 398,245,497 | ||
| NUTEX 健康公司 | ||||||
| 简明的合并资产负债表 | ||||||
| （未经审计） | ||||||
| 2024年3月31日 | 2023年12月31日 | |||||
| 资产 | ||||||
| 流动资产： | ||||||
| 现金和现金等价物 | $ | 30,006,419 | $ | 22,002,056 | ||
| 应收账款 | 61,533,245 | 58,624,301 | ||||
| 应收账款—关联方 | 4,213,847 | 4,152,068 | ||||
| 库存 | 2,975,486 | 3,390,584 | ||||
| 预付费用和其他流动资产 | 1,629,346 | 2,679,394 | ||||
| 流动资产总额 | 100,358,343 | 90,848,403 | ||||
| 财产和设备，净额 | 80,570,705 | 81,387,649 | ||||
| 运营使用权资产 | 11,580,253 | 11,853,082 | ||||
| 为使用权资产融资 | 173,920,659 | 176,146,329 | ||||
| 无形资产，净额 | 20,102,371 | 20,512,636 | ||||
| 商誉，净额 | 17,066,263 | 17,066,263 | ||||
| 其他资产 | 685,260 | 431,135 | ||||
| 总资产 | $ | 404,283,854 | $ | 398,245,497 | ||
| 负债和权益 | ||||||
| 流动负债： | ||||||
| 应付账款 | $ | 17,217,905 | $ | 18,899,196 | ||
| 应付账款—关联方 | 6,856,962 | 6,382,197 | ||||
| 信贷额度 | 2,777,128 | 3,371,676 | ||||
| 长期债务的当前部分 | 9,388,455 | 10,808,721 | ||||
| 经营租赁负债，流动部分 | 1,586,904 | 1,579,987 | ||||
| 融资租赁负债，流动部分 | 4,366,696 | 4,315,979 | ||||
| 应计费用和其他流动负债 | 17,694,134 | 12,955,296 | ||||
| 流动负债总额 | 59,888,184 | 58,313,052 | ||||
| 长期债务，净额 | 26,308,017 | 26,314,733 | ||||
| 认股权证责任 | 5,060,810 | — | ||||
| 经营租赁负债，净额 | 15,097,284 | 15,479,639 | ||||
| 融资租赁负债，净额 | 212,867,062 | 213,886,213 | ||||
| 递延所得税负债 | 5,050,347 | 5,145,754 | ||||
| 负债总额 | 324,271,704 | 319,139,391 | ||||
| 承付款和意外开支 | ||||||
| 股权： | ||||||
| 普通股，面值0.001美元；已授权9.5亿股；49,719,375和 | 49,719 | 45,112 | ||||
| 额外的实收资本 | 472,405,834 | 470,480,617 | ||||
| 累计赤字 | (409,436,614) | (409,072,539) | ||||
| Nutex 健康公司股权 | 63,018,939 | 61,453,190 | ||||
| 非控股权益 | 16,993,211 | 17,652,916 | ||||
| 权益总额 | 80,012,150 | 79,106,106 | ||||
| 负债和权益总额 | $ | 404,283,854 | $ | 398,245,497 | ||
| NUTEX HEALTH INC. | ||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||
| (Unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Revenue: | ||||||
| Hospital division | $ | 60,029,369 | $ | 49,288,164 | ||
| Population health management division | 7,424,418 | 7,041,253 | ||||
| Total revenue | 67,453,787 | 56,329,417 | ||||
| Operating costs and expenses: | ||||||
| Payroll and benefits | 27,003,144 | 25,836,673 | ||||
| Contract services | 11,319,454 | 9,189,331 | ||||
| Medical supplies | 5,321,842 | 4,023,882 | ||||
| Depreciation and amortization | 4,186,202 | 3,993,747 | ||||
| Other | 9,465,967 | 8,438,061 | ||||
| Total operating costs and expenses | 57,296,609 | 51,481,694 | ||||
| Gross profit | 10,157,178 | 4,847,723 | ||||
| Corporate and other costs: | ||||||
| Facilities closing costs | – | 217,266 | ||||
| Stock-based compensation expense | 49,167 | 1,900,000 | ||||
| General and administrative expenses | 8,658,410 | 7,175,544 | ||||
| Total corporate and other costs | 8,707,577 | 9,292,810 | ||||
| Operating income (loss) | 1,449,601 | (4,445,087) | ||||
| Interest expense, net | 4,444,362 | 3,140,089 | ||||
| Gain on warrant liability | (2,600,747) | – | ||||
| Other (income) expense | (241,192) | 247,455 | ||||
| Loss before taxes | (152,822) | (7,832,631) | ||||
| Income tax expense (benefit) | 389,665 | (910,659) | ||||
| Net loss | (542,487) | (6,921,972) | ||||
| Less: net loss attributable to noncontrolling interests | (178,412) | (1,774,693) | ||||
| Net loss attributable to Nutex Health Inc. | $ | (364,075) | $ | (5,147,279) | ||
| Loss per common share: | ||||||
| Basic | $ | (0.01) | $ | (0.12) | ||
| Diluted | $ | (0.01) | $ | (0.12) | ||
| NUTEX 健康公司 | ||||||
| 简明合并运营报表 | ||||||
| （未经审计） | ||||||
| 截至3月31日的三个月 | ||||||
| 2024 | 2023 | |||||
| 收入： | ||||||
| 医院部门 | $ | 60,029,369 | $ | 49,288,164 | ||
| 人口健康管理司 | 7,424,418 | 7,041,253 | ||||
| 总收入 | 67,453,787 | 56,329,417 | ||||
| 运营成本和支出： | ||||||
| 工资和福利 | 27,003,144 | 25,836,673 | ||||
| 合同服务 | 11,319,454 | 9,189,331 | ||||
| 医疗用品 | 5,321,842 | 4,023,882 | ||||
| 折旧和摊销 | 4,186,202 | 3,993,747 | ||||
| 其他 | 9,465,967 | 8,438,061 | ||||
| 运营成本和支出总额 | 57,296,609 | 51,481,694 | ||||
| 毛利 | 10,157,178 | 4,847,723 | ||||
| 公司费用和其他费用： | ||||||
| 设施关闭费用 | — | 217,266 | ||||
| 股票薪酬支出 | 49,167 | 1,900,000 | ||||
| 一般和管理费用 | 8,658,410 | 7,175,544 | ||||
| 公司费用和其他费用总额 | 8,707,577 | 9,292,810 | ||||
| 营业收入（亏损） | 1,449,601 | (4,445,087) | ||||
| 利息支出，净额 | 4,444,362 | 3,140,089 | ||||
| 认股权证责任收益 | (2,600,747) | — | ||||
| 其他（收入）支出 | (241,192) | 247,455 | ||||
| 税前亏损 | (152,822) | (7,832,631) | ||||
| 所得税支出（福利） | 389,665 | (910,659) | ||||
| 净亏损 | (542,487) | (6,921,972) | ||||
| 减去：归属于非控股权益的净亏损 | (178,412) | (1,774,693) | ||||
| 归因于 Nutex Health Inc. 的净亏损 | $ | (364,075) | $ | (5,147,279) | ||
| 每股普通股亏损： | ||||||
| 基本 | $ | (0.01) | $ | (0.12) | ||
| 稀释 | $ | (0.01) | $ | (0.12) | ||
| NUTEX HEALTH INC. | ||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
| (Unaudited) | ||||||
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Cash flows from operating activities: | ||||||
| Net loss | $ | (542,487) | $ | (6,921,972) | ||
| Adjustments to reconcile net loss to net cash from operating activities: | ||||||
| Depreciation and amortization | 4,186,202 | 3,993,747 | ||||
| Gain on warrant liability | (2,600,747) | – | ||||
| Amortization of debt issuance costs | – | 6,738 | ||||
| Stock-based compensation expense | 49,167 | 1,900,000 | ||||
| Deferred tax benefit | (95,407) | (910,659) | ||||
| Debt accretion expense | 365,104 | – | ||||
| Loss on lease termination | – | 58,211 | ||||
| Non-cash lease expense (income) | (102,609) | 40,545 | ||||
| Changes in operating assets and liabilities, net of the effects of acquisitions: | ||||||
| Accounts receivable | (2,908,944) | 6,620,249 | ||||
| Accounts receivable – related party | (61,779) | (100) | ||||
| Inventories | 415,098 | 47,840 | ||||
| Prepaid expenses and other current assets | 795,923 | 1,040,753 | ||||
| Accounts payable | (1,681,291) | (8,565,577) | ||||
| Accounts payable – related party | 474,765 | 9,636 | ||||
| Accrued expenses and other current liabilities | 4,757,864 | 3,732,602 | ||||
| Net cash from operating activities | 3,050,859 | 1,052,013 | ||||
| Cash flows from investing activities: | ||||||
| Acquisitions of property and equipment | (733,323) | (4,376,983) | ||||
| Cash related to deconsolidation of Real Estate Entities | – | (1,039,157) | ||||
| Net cash from investing activities | (733,323) | (5,416,140) | ||||
| Cash flows from financing activities: | ||||||
| Proceeds from lines of credit | – | 49,414 | ||||
| Proceeds from notes payable | 2,915,000 | 7,551,506 | ||||
| Repayments of lines of credit | (594,548) | – | ||||
| Repayments of notes payable | (4,386,398) | (2,209,678) | ||||
| Repayments of finance leases | (968,434) | (936,703) | ||||
| Proceeds from common stock issuance, net issuance costs | 9,202,500 | – | ||||
| Members' contributions | – | 28,000 | ||||
| Members' distributions | (481,293) | (1,537,141) | ||||
| Net cash from financing activities | 5,686,827 | 2,945,398 | ||||
| Net change in cash and cash equivalents | 8,004,363 | (1,418,729) | ||||
| Cash and cash equivalents – beginning of the period | 22,002,056 | 34,255,264 | ||||
| Cash and cash equivalents – end of the period | $ | 30,006,419 | $ | 32,836,535 | ||
| NUTEX 健康公司 | ||||||
| 简明的合并现金流量表 | ||||||
| （未经审计） | ||||||
| 截至3月31日的三个月 | ||||||
| 2024 | 2023 | |||||
| 来自经营活动的现金流： | ||||||
| 净亏损 | $ | (542,487) | $ | (6,921,972) | ||
| 为将净亏损与经营活动产生的净现金进行对账而进行的调整： | ||||||
| 折旧和摊销 | 4,186,202 | 3,993,747 | ||||
| 认股权证责任收益 | (2,600,747) | — | ||||
| 债务发行成本的摊销 | — | 6,738 | ||||
| 股票薪酬支出 | 49,167 | 1,900,000 | ||||
| 递延所得税优惠 | (95,407) | (910,659) | ||||
| 债务增加费用 | 365,104 | — | ||||
| 租赁终止时的损失 | — | 58,211 | ||||
| 非现金租赁费用（收入） | (102,609) | 40,545 | ||||
| 扣除收购影响的运营资产和负债的变化： | ||||||
| 应收账款 | (2,908,944) | 6,620,249 | ||||
| 应收账款—关联方 | (61,779) | (100) | ||||
| 库存 | 415,098 | 47,840 | ||||
| 预付费用和其他流动资产 | 795,923 | 1,040,753 | ||||
| 应付账款 | (1,681,291) | (8,565,577) | ||||
| 应付账款-关联方 | 474,765 | 9,636 | ||||
| 应计费用和其他流动负债 | 4,757,864 | 3,732,602 | ||||
| 来自经营活动的净现金 | 3,050,859 | 1,052,013 | ||||
| 来自投资活动的现金流： | ||||||
| 购置财产和设备 | (733,323) | (4,376,983) | ||||
| 与房地产实体解散相关的现金 | — | (1,039,157) | ||||
| 来自投资活动的净现金 | (733,323) | (5,416,140) | ||||
| 来自融资活动的现金流： | ||||||
| 来自信贷额度的收益 | — | 49,414 | ||||
| 应付票据的收益 | 2,915,000 | 7,551,506 | ||||
| 信贷额度的还款 | (594,548) | — | ||||
| 应付票据的还款 | (4,386,398) | (2,209,678) | ||||
| 偿还融资租赁 | (968,434) | (936,703) | ||||
| 普通股发行收益，净发行成本 | 9,202,500 | — | ||||
| 成员的捐款 | — | 28,000 | ||||
| 成员分布 | (481,293) | (1,537,141) | ||||
| 来自融资活动的净现金 | 5,686,827 | 2,945,398 | ||||
| 现金和现金等价物的净变化 | 8,004,363 | (1,418,729) | ||||
| 现金及现金等价物——期初 | 22,002,056 | 34,255,264 | ||||
| 现金及现金等价物——期末 | $ | 30,006,419 | $ | 32,836,535 | ||
Non-GAAP Financial Measures (Unaudited)
非公认会计准则财务指标（未经审计）
EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance.
息税折旧摊销前利润（EBITDA）和调整后的 我们的财务报表的管理层和外部用户，例如行业分析师、投资者、贷款人和评级机构，将息税折旧摊销前利润和调整后息税折旧摊销前利润用作补充性非公认会计准则财务指标。我们认为，息税折旧摊销前利润和调整后息税折旧摊销前利润很有用，因为它使我们能够更有效地评估运营业绩。
We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization.
我们将息税折旧摊销前利润定义为归属于Nutex Health Inc.的净收益（亏损）加上利息支出、所得税、折旧和摊销。
We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense, any acquisition-related costs and impairments. A reconciliation of net income to EBITDA and Adjusted EBITDA is included below. EBITDA and Adjusted EBITDA are not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies.
我们将调整后的息税折旧摊销前利润定义为归属于Nutex Health Inc.的净收益（亏损）加上净利息支出、所得税、折旧和摊销，并进一步调整了股票薪酬、某些特定支出项目、任何与收购相关的成本和减值。净收入与息税折旧摊销前利润和调整后息税折旧摊销前利润的对账如下所示。息税折旧摊销前利润和调整后息税折旧摊销前利润不打算作为美国公认会计准则绩效指标的替代方案，也可能无法与其他公司提出的类似标题的指标进行比较。
| Three Months Ended March 31, | ||||||
| 2024 | 2023 | |||||
| Reconciliation of net loss attributable to Nutex Health Inc. to Adjusted | ||||||
| Net loss attributable to Nutex Health Inc. | $ | (364,075) | $ | (5,147,279) | ||
| Depreciation and amortization | 4,186,202 | 3,993,747 | ||||
| Interest expense, net | 4,444,362 | 3,140,089 | ||||
| Income tax expense (benefit) | 389,665 | (910,659) | ||||
| Allocation to noncontrolling interests | (1,544,173) | (755,310) | ||||
| EBITDA | 7,111,981 | 320,588 | ||||
| Facilities closing costs | – | 217,266 | ||||
| Gain on warrant liability | (2,600,747) | – | ||||
| Stock-based compensation expense | 49,167 | 1,900,000 | ||||
| Adjusted EBITDA | $ | 4,560,401 | $ | 2,437,854 | ||
| 截至3月31日的三个月 | ||||||
| 2024 | 2023 | |||||
| 归属于Nutex Health Inc.的净亏损与调整后的对账 | ||||||
| 归因于 Nutex Health Inc. 的净亏损 | $ | (364,075) | $ | (5,147,279) | ||
| 折旧和摊销 | 4,186,202 | 3,993,747 | ||||
| 利息支出，净额 | 4,444,362 | 3,140,089 | ||||
| 所得税支出（福利） | 389,665 | (910,659) | ||||
| 对非控股权益的分配 | (1,544,173) | (755,310) | ||||
| EBITDA | 7,111,981 | 320,588 | ||||
| 设施关闭费用 | — | 217,266 | ||||
| 认股权证责任收益 | (2,600,747) | — | ||||
| 股票薪酬支出 | 49,167 | 1,900,000 | ||||
| 调整后 EBITDA | $ | 4,560,401 | $ | 2,437,854 | ||
About Nutex Health Inc.
关于 Nutex Health Inc
Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division.
Nutex Health Inc.（纳斯达克股票代码：NUTX）总部位于德克萨斯州休斯顿，成立于2011年，是一家医疗保健管理和运营公司，分为两个部门：医院部和人口健康管理部。
The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in nine states.
医院部拥有、开发和运营创新的医疗保健模式，包括微型医院、专科医院和医院门诊部（HOPD）。该部门在九个州拥有并运营21个设施。
The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently.
人口健康管理部门拥有并运营独立医生协会（IPA）等提供者网络。通过我们的管理服务组织（MSO），我们为我们的附属医院和医生团体提供管理、行政和其他支持服务。我们基于云的专有技术平台汇总了多个设置、信息系统和来源的临床和索赔数据，以创建患者和提供者的整体视图，使我们能够更有效地提供更高质量的护理。
Forward-Looking Statements
前瞻性陈述
Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2023 under the heading "Risk Factors" in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.
本新闻稿中包含的某些陈述和信息构成1995年《私人证券诉讼法》所指的 “前瞻性陈述”。在本新闻稿中使用 “将”、“可能导致”、“预期”、“将继续”、“预期”、“估计”、“预计”、“打算”、“目标” 或类似表述的词语或短语旨在识别1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。此类陈述受某些已知和未知风险以及不确定性的影响，其中许多风险是公司无法控制的。此类不确定性和风险包括但不限于我们成功执行增长战略的能力、法律或法规的变化，包括在《无意外法》下实施的临时最终和最终规则、经济状况、对管理层的依赖、对股东的稀释、资本缺乏、快速增长对公司的影响以及管理层有效应对公司产品和服务增长和需求的能力、新开发的技术、公司的能力竞争，冲突对关联方交易、监管事务、技术保护、缺乏行业标准、竞争的影响以及公司获得未来融资的能力感兴趣。截至2023年12月31日止年度的10-K表年度报告第一部分第IA项中的 “风险因素” 标题以及不时向美国证券交易委员会提交的其他文件中讨论了可能影响未来业绩的广泛因素清单。这些因素可能会对公司的财务业绩产生重大不利影响，并可能导致公司未来时期的实际业绩与本新闻稿中表达的任何观点或陈述存在重大差异。
View original content:https://www.prnewswire.com/news-releases/nutex-health-reports-first-quarter-2024-financial-results-302140557.html
SOURCE Nutex Health, Inc.
来源 Nutex Health, Inc.